
Akhil Santhosh
Apr 8, 2025, 11:42
Akhil Santhosh: Lu-Edotreotide Improves PFS vs. Everolimus in Grade 1-2 NET
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Lu-Edotreotide improves PFS compared to everolimus in both treatment naive and pretreated patients in grade1-2 NET. OS results immature: Compete phase 3 trial.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 18:39
Apr 14, 2025, 18:22
Apr 14, 2025, 18:21
Apr 14, 2025, 18:16
Apr 14, 2025, 18:13
Apr 14, 2025, 18:08
Apr 14, 2025, 17:57
Apr 14, 2025, 17:39